Literature DB >> 7948554

Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis.

R E Huebner1, M F Schein, C A Hall, S A Barnes.   

Abstract

A total of 479 human immunodeficiency virus (HIV)-infected persons at an HIV clinic in Florida and a tuberculosis clinic in New Jersey were skin-tested with tuberculin, tetanus toxoid, mumps antigen, and Candida antigen in a study of the prevalence of delayed-type hypersensitivity (DTH) anergy and the usefulness of two-step tuberculin testing in this population. Of the patients tested, 12% had a positive (> or = 5-mm) response to tuberculin; 57%, 45%, and 35% had a positive (> or = 3-mm) response to Candida antigen, tetanus toxoid, and mumps antigen, respectively; and 31% were anergic (< 3 mm of induration in response to each antigen). In a multivariate logistic regression model, anergy was significantly associated with a history of Kaposi's sarcoma, Pneumocystis carinii pneumonia, or oral candidiasis and with White race. Anergy was four times and 15 times as likely for persons with CD4+ T-lymphocyte counts of 200-400/mm3 and < 200/mm3, respectively, as for persons with > 499 CD4+ T lymphocytes/mm3. Of 103 patients who were tuberculin-tested a second time after their initial test result was negative, seven had > or = 5 mm of induration in response to the second test; only one of these patients was anergic at the initial screening. The findings of this study indicate that DTH antigens should be used in conjunction with tuberculin testing and that two-step tuberculin testing is not an alternative to anergy testing but may be useful for the detection of infection with Mycobacterium tuberculosis in nonanergic HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948554     DOI: 10.1093/clinids/19.1.26

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Tuberculosis: 11. Nosocomial disease.

Authors:  K Schwartzman; D Menzies
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

2.  Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis.

Authors:  R C Hendrickson; J F Douglass; L D Reynolds; P D McNeill; D Carter; S G Reed; R L Houghton
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus.

Authors:  A S Rogers; J H Ellenberg; S D Douglas; L Henry-Reid; L Peralta; C M Wilson
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Clinical investigation: increased serum stromal derived factor 1 alpha levels in pulmonary tuberculosis.

Authors:  K Mizuno; W Matsuyama; H Mitsuyama; M Watanabe; I Higashimoto; M Osame; K Arimura
Journal:  Clin Exp Immunol       Date:  2005-03       Impact factor: 4.330

5.  CD4+ T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures.

Authors:  Lillian Seu; James A Mobley; Paul A Goepfert
Journal:  Clin Immunol       Date:  2017-05-25       Impact factor: 3.969

Review 6.  Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses.

Authors:  Fadi Saade; Stacey Ann Gorski; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-12       Impact factor: 5.217

7.  Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection.

Authors:  Paolo Scarpellini; Silvana Tasca; Laura Galli; Alberto Beretta; Adriano Lazzarin; Claudio Fortis
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

8.  Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study.

Authors:  Keren Middelkoop; Linda-Gail Bekker; Hua Liang; Lisa D H Aquino; Elaine Sebastian; Landon Myer; Robin Wood
Journal:  BMC Infect Dis       Date:  2011-06-01       Impact factor: 3.090

9.  BCG-specific IgG-secreting peripheral plasmablasts as a potential biomarker of active tuberculosis in HIV negative and HIV positive patients.

Authors:  Senait Ashenafi; Getachew Aderaye; Martha Zewdie; Rubhana Raqib; Amsalu Bekele; Isabelle Magalhaes; Beede Lema; Meseret Habtamu; Rokeya Sultana Rekha; Getachew Aseffa; Markus Maeurer; Abraham Aseffa; Mattias Svensson; Jan Andersson; Susanna Brighenti
Journal:  Thorax       Date:  2012-08-24       Impact factor: 9.139

10.  Biomarkers for clinical and incipient tuberculosis: performance in a TB-endemic country.

Authors:  Ajay Wanchu; Yuxin Dong; Sunil Sethi; V P Myneedu; Arthur Nadas; Zhentong Liu; John Belisle; Suman Laal
Journal:  PLoS One       Date:  2008-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.